Hope Saves Millions in New Cancer Vaccine

American pharmaceutical companies Merck and Moderna announced positive results from the final phase of an experimental treatment for skin cancer using messenger RNA (mRNA) technology. The treatment, called "Entisaiman Autogen," showed a significant statistical improvement in relapse-free survival when combined with the immunotherapy drug Keytruda, compared to using Keytruda alone in patients who had previous surgeries. These are the first-ever results of a cancer treatment using mRNA technology in phase three. The therapy is personalized based on the specific mutations in each patient's tumors to enhance the immune system's ability to recognize and attack cancer cells.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل